Your CER or PER Is Not a One-Time Deliverable: Why Continuous Evidence Management Matters
5 min czytania

A device can remain unchanged after certification while new information raises questions about the evidence supporting it. Clinical guidelines may change the relevance of a comparator. Published studies may challenge a claimed benefit, and complaints may reveal outcomes that the original evaluation did not anticipate. Adding this information to a Clinical Evaluation Report (CER) or Performance Evaluation Report (PER) does not explain whether existing conclusions still hold. 

Manufacturers need to keep clinical and performance evaluation current after initial conformity assessment. Continuous evidence management requires manufacturers to assess how new evidence affects the documented conclusions during each review. Where those conclusions remain unchanged, the reasons for retaining them should be recorded. 

Why Clinical and Performance Evidence Must Evolve

Under EU MDR, Regulation 2017/745, clinical evaluation assesses data relevant to the intended purpose, clinical safety, performance and benefits of a medical device. The Clinical Evaluation Report, or CER, records the evidence appraisal and conclusions on benefits and risks under Article 61 and Annex XIV. 

In vitro diagnostic devices, or IVDs, follow a separate framework under EU IVDR, Regulation 2017/746. A Performance Evaluation Plan, or PEP, guides the assessment of scientific validity, analytical performance and clinical performance. The Performance Evaluation Report, or PER, records the evidence and conclusions supporting the intended purpose under Article 56 and Annex XIII. 

These evaluations continue throughout the product lifecycle. Revised guidelines may change the role of a device in clinical practice. For IVDs, changes in disease prevalence or the population being tested may affect how results are interpreted. 

Each reassessment should establish whether the evidence still supports the intended claims and whether new uncertainties have emerged. It should also consider whether the balance between benefits and risks remains acceptable. 

What Can Undermine an Otherwise Complete CER or PER?

Outdated context. A literature update may add new studies without reassessing the device against current clinical practice, relevant alternatives, and state-of-the-art safety and performance expectations. The clinical evaluation requirements in EU MDR Annex XIV call for systematic appraisal and analysis of relevant evidence. 

Unexamined post-market signals. A complaint trend may appear in a PMS report without being assessed in the clinical or performance evaluation. Manufacturers need to evaluate the reliability of the signal and its potential impact on safety, performance, and existing conclusions. 

Changes to Claims or intended use. Expanded indications, software modifications affecting performance, or a new specimen type may require additional evidence to support the affected claims. For an IVD, performance evaluation must consider whether evidence continues to support the claimed application across scientific validity, analytical performance and clinical performance. 

Disconnected decisions. Clinical, quality, and regulatory teams may assess the same finding separately, leaving inconsistent conclusions across the CER or PER, risk management file, and labelling. 

Consider an IVD whose design and intended population remain unchanged, but new treatment guidelines alter when testing is recommended. Its PER may need to reassess the clinical relevance of existing claims despite no modification to the test. 

PMS, PMCF and PMPF: Turning Observations into Decisions

Post market surveillance, or PMS, collects and analyses information about products in use. For medical devices, Post-market Clinical Follow-up (PMCF) proactively collects and evaluates clinical data to confirm continued safety and performance and identify emerging risks. 

For IVDs, Post-market Performance Follow-up (PMPF) collects and assesses scientific and performance data to support ongoing performance evaluation. EU IVDR Article 56 and Annex XIII connect this evaluation with PMS and PMPF. The nonbinding MDCG 2022-2 guidance on IVD clinical evidence explains how new information informs the process. 

A credible safety signal may change conclusions about benefits and risks. Research involving an IVD may question the association between an analyte and a clinical condition. It may also show that findings from one care setting do not support claims in another. Manufacturers should document the evidence, its limitations and the resulting decision. 

PMCF and PMPF methods depend on the device, its evidence gaps and applicable requirements. Where either is considered inapplicable, the evaluation documentation should include a justification specific to the device. Post market clinical and performance follow up documentation helps connect the findings with the CER or PER, risk management and future evidence priorities. 

How Often Should a CER or PER Be Updated?

EU MDR Article 61, paragraph 11, requires clinical evaluation and its documentation to be updated throughout the lifecycle using relevant PMCF and PMS data. It does not impose an annual CER update for every device. Its specific annual provision concerns PMCF evaluation reports for Class III and implantable devices and, where indicated, summaries of safety and clinical performance. 

EU IVDR Article 56, paragraph 6, also requires lifecycle updates. For Class C and D IVDs, the PER must be updated when necessary and at least annually. For Class A and B IVDs, performance evaluation and its documentation must be updated throughout the lifecycle. The provision does not specify an annual PER update interval for these classes. 

A justified review schedule helps organize this work. Significant new evidence may require reassessment before the next planned revision. 

Making Continuous Evidence Management Operational

Evidence governance starts by defining who assesses new evidence, who approves the resulting conclusions, and who ensures that affected documents are updated. 

Assign responsibility and define review triggers: Assign clear decision ownership, with defined inputs from clinical or performance evaluation, PMS, risk management, product and quality functions. Establish routine surveillance alongside event-driven triggers: changed indications, revised clinical guidelines, literature challenging a claim, unexpected performance patterns or design modifications. These are process recommendations; EU regulations do not prescribe a single organizational model. 

Document evidence decisions: Maintain an evidence decision log alongside the literature inventory. For each consequential finding that could affect safety, performance, or a supported claim, record its source, critical appraisal, affected claim or risk, decision, rationale, owner and follow-up. This provides a traceable rationale for retaining or revising existing conclusions. The log supports, but does not replace, required CER or PER updates. 

Prioritize evidence gaps: Prioritize evidence gaps by potential consequences for patient or user safety, claimed benefits and residual uncertainty. A low-relevance publication may require only a recorded assessment. A credible signal challenging clinical performance may justify a targeted study, additional post-market follow-up or reassessment of labelling. New investigations are not automatically necessary for every gap. 

Maintain traceability: Manual trackers or controlled documents can support this approach if ownership, review history and traceability are reliable. The objective is a repeatable scientific decision process, without creating unnecessary administrative work. 

How Freyr Supports Continuous Clinical and Performance Evaluation

Freyr supports medical device and IVD manufacturers in maintaining clinical and performance documentation as evidence evolves. Its Clinical and Performance Evaluation services include CER and PER preparation and updates, evidence gap assessments, systematic literature reviews and state-of-the-art evaluation. Freyr also supports PMCF and PMPF planning and evidence assessment, helping manufacturers connect post-market findings with regulatory documentation and risk management. 

For manufacturers managing multiple products or responding to notified body questions, coordinated review and traceable updates can help establish which conclusions remain adequately supported and which uncertainties call for further action. Explore Freyr's services to discuss a proportionate lifecycle evidence management approach. 

Subskrybuj bloga Freyr

Polityka prywatności